Monte Rosa Therapeutics宣布发表《科学》封面上的突破性新发现，题为“挖掘CRBN目标空间重新定义了分子胶质诱导的新底识别规则”

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the publication of groundbreaking new discoveries featured on the cover of Science. The research article, "Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition," details how Monte Rosa's proprietary artificial intelligence (AI) and machine learning (ML) engine has uncovered a broad range of human proteins potentially accessible to cereblon (CRBN)-based degradation, spanning diverse protein domains and classes. These findings dramatically expand the actionable target space for MGD drug discovery.